DEFA14A: Ensysce Biosciences Clarifies Broker Voting Rights for Annual Meeting Proposals

Ensysce Biosciences has issued a supplement to its proxy statement clarifying that brokers have discretionary voting authority on Proposals 2, 4, and 5 at the upcoming annual meeting.

Summary

• Ensysce Biosciences has released a supplement to its proxy statement for the 2024 Annual Meeting of Stockholders.
• The supplement clarifies that the New York Stock Exchange (NYSE) has designated Proposals 2 (Reverse Stock Split), 4 (ratification of independent accounting firm), and 5 (Additional Solicitation Proposal) as routine matters.
• This designation allows brokers to vote on these proposals at their discretion if they do not receive instructions from shareholders.
• The original proxy statement only mentioned discretionary voting for Proposal 4, but this supplement corrects that to include Proposals 2 and 5.
• The supplement revises the proxy statement to reflect this change in two places: in the Q&A section and in the voting procedures chart.
• The annual meeting is scheduled for November 21, 2024, at 9:00 a.m., Pacific Time.

Sentiment

Score: 7

Explanation: The document is a routine clarification of voting procedures, which is neutral to slightly positive as it ensures transparency and compliance.

Positives

• The supplement provides clarity to shareholders regarding broker voting rights.
• The company is ensuring that all shareholders are aware of the voting procedures.

Risks

• If shareholders do not provide voting instructions to their brokers, their shares may be voted at the broker's discretion on Proposals 2, 4, and 5.
• There is a risk that broker votes may not align with the preferences of individual shareholders.

Industry Context

This announcement is typical for companies holding annual meetings and needing to clarify voting procedures, especially when dealing with broker discretionary voting.

Comparison to Industry Standards

• Many public companies face similar situations regarding broker voting rights, particularly for routine matters.
• The clarification provided by Ensysce is consistent with standard practices to ensure transparency and compliance with NYSE rules.
• Other companies such as Amgen, Gilead, and Biogen also have to deal with similar issues regarding broker voting rights.

Stakeholder Impact

• Shareholders are directly impacted by the clarification of broker voting rights.
• Brokers are impacted by the clarification of their discretionary voting authority.

Next Steps

• Shareholders should review the supplement and provide voting instructions to their brokers if they wish to have their votes counted on Proposals 2, 4, and 5.
• The company will hold its Annual Meeting on November 21, 2024.

Key Dates

Keywords

proxy statement, annual meeting, discretionary voting, broker non-votes, reverse stock split, independent accounting firm, solicitation proposal, NYSE